Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027

エピジェネティクスのグローバル市場予測(~2027):キット&試薬、酵素、機器&付属品、ソフトウェア、サービス

◆タイトル:Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027
◆商品コード:BT2775-22
◆調査・発行会社:MarketsandMarkets
◆発行日:2022年7月15日
◆ページ数:239
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥0見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社の最新調査レポートによると、世界のエピジェネティクス市場規模は、2022年17億ドルから2027年39億ドルまで年平均18.1%拡大すると見込まれています。当書ではエピジェネティクスの世界市場を総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別(キット&試薬、酵素、機器&付属品、ソフトウェア、サービス)分析、方法別(DNAメチル化、ヒストン修飾、その他)分析、技術別(NGS、PCR&qPCR、質量分析、超音波処理、その他)分析、用途別(腫瘍、代謝性疾患、免疫、発生生物学、心血管疾患)分析、地域別分析、競争状況、企業情報など、以下の項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のエピジェネティクス市場規模:製品・サービス別(キット&試薬、酵素、機器&付属品、ソフトウェア、サービス)
・世界のエピジェネティクス市場規模:方法別(DNAメチル化、ヒストン修飾、その他)
・世界のエピジェネティクス市場規模:技術別(NGS、PCR&qPCR、質量分析、超音波処理、その他)
・世界のエピジェネティクス市場規模:用途別(腫瘍、代謝性疾患、免疫、発生生物学、心血管疾患)
・世界のエピジェネティクス市場規模:地域別
・競争状況
・企業情報

“The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period.”
Expanding non-oncology applications of epigenetics research is expected to open up new avenues of market expansion. Recent studies on epigenetics have been targeted toward periodontology, focusing on DNA methylation analysis. Increasing advancements in sequencing technology have opened new avenues for epigenetic studies enabling the assessment of specific genes and genome-wide analyses. With technological advancements, epigenetics research is anticipated to provide crucial information for developing dental medicine and expand the scope of ongoing large-scale research projects.

“The kits & reagents segment dominates the epigenetics market through the study period of 2020-2027.”
Based on product & service, the global epigenetics market is segmented into kits & reagents, enzymes, instruments and accessories, software, and service. The dominance of kits & reagents segment is attributed to affordable and convenient kits introduced by the market participants. This is expected to suffice the significant elevation in the number of epigenetics research activities conducted in the past few years. Additionally, market players are expanding their product offerings around epigenetics antibodies, which is further expected to supplement the segment’s dominance.

“The histone modifications segment will witness the highest growth in the epigenetics market during the forecast period.”
Based on method, the global epigenetics market is segmented into DNA methylation, histone modifications, and other methods. Histone modifications include different approaches such as, methylation, citrullination, ubiquitination, acetylation, and phosphorylation. Additionally, research professionals are focusing on understanding the potential of histone modifications in oncology which is expected to promote the segment growth through 2022 to 2027.

“North America dominated the epigenetics market in 2021.”
Geographically, the epigenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the largest share of the epigenetics market. North America harbors majority of the key market players leading to maturity of epigenetics market in this region. Also, robust government support for academic & research activities offer opportunity for the key market players to introduce cutting-edge epigenetics products, further intensifying regional market competition.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1: 37%, Tier 2: 23%, and Tier 3: 40%
• By Designation – C-level: 32%, D-level: 26%, and Others: 42%
• By Region – North America: 35%, Europe: 25%, Asia Pacific: 20%, Latin America: 12%, and the Middle East and Africa: 8%

List of Companies Profiled in the Report
• Thermo Fisher Scientific (US)
• Merck KGaA (Germany)
• Illumina, Inc. (US)
• PacBio (US)
• Abcam plc (UK)
• Active Motif, Inc. (US)
• Bio-Rad Laboratories (US)
• Promega Corporation (US)
• PerkinElmer (US)
• Qiagen (Germany)
• New England Biolabs (US)
• Zymo Research Corporation (US)
• Diagenode (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• EpiGentek Group Inc. (US)
• EpiCypher (US)
• Everon Life Sciences (India)
• Fios Genomics (UK)
• GenomeScan (Netherlands)
• Creative Biogene (US)

Research Coverage:
This report provides a detailed picture of the global epigenetics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, method, technique, application, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total epigenetics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on epigenetics offered by the top 20 players in the epigenetics market. The report analyses the epigenetics market by product & service, method, technique, application, end user, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various epigenetics across key geographic regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the epigenetics market.
• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the epigenetics market.

【レポートの目次】

1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS AND EXCLUSIONS 34
1.3 MARKET SCOPE 35
FIGURE 1 EPIGENETICS MARKET 35
1.3.1 YEARS CONSIDERED FOR THE STUDY 36
1.4 CURRENCY 36
1.5 LIMITATIONS 36
1.6 STAKEHOLDERS 37
1.7 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
FIGURE 2 RESEARCH DESIGN 38
2.1.1 SECONDARY DATA 39
2.1.2 PRIMARY DATA 40
FIGURE 3 EPIGENETICS MARKET: BREAKDOWN OF PRIMARIES 40
2.2 MARKET SIZE ESTIMATION 41
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF EPIGENETICS IN THE MARKET 41
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 41
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 42
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 43
FIGURE 7 EPIGENETICS MARKET: CAGR PROJECTIONS, 2022–2027 44
FIGURE 8 EPIGENETICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 44
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 45
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 46
FIGURE 10 DATA TRIANGULATION METHODOLOGY 46
2.5 INSIGHTS FROM PRIMARIES 47
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 47
2.6 RESEARCH ASSUMPTIONS 47
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 48
2.7 RISK ANALYSIS 48
3 EXECUTIVE SUMMARY 49
FIGURE 12 EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2021 VS. 2027 (USD MILLION) 49
FIGURE 13 EPIGENETICS MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION) 50
FIGURE 14 EPIGENETICS MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION) 50
FIGURE 15 EPIGENETICS MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION) 51
FIGURE 16 EPIGENETICS MARKET, BY END USER, 2021 VS. 2027 (USD MILLION) 51
FIGURE 17 GEOGRAPHICAL SNAPSHOT: EPIGENETICS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 EPIGENETICS MARKET OVERVIEW 53
FIGURE 18 GROWING USE OF EPIGENETIC ENZYMES IN DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH 53
4.2 NORTH AMERICA: EPIGENETICS MARKET SHARE, BY PRODUCT & SERVICE AND COUNTRY (2021) 54
FIGURE 19 KITS & REAGENTS ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN EPIGENETICS MARKET IN 2021 54
4.3 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD, 2021 VS. 2027 (USD MILLION) 55
FIGURE 20 DNA METHYLATION TO DOMINATE THE NORTH AMERICAN MARKET TILL 2027 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 EPIGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
TABLE 1 EPIGENETICS MARKET: IMPACT ANALYSIS 57
5.2.1 DRIVERS 57
5.2.1.1 Epigenetic enzymes gaining traction in drug discovery & development 57
TABLE 2 KEY EPIGENETIC ENZYMES FOR REPURPOSING DRUGS 58
5.2.1.2 Rising investments, funds, and grants for epigenetics research 59
5.2.1.3 Declining costs of genome sequencing 60
FIGURE 22 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001–2020 60
5.2.2 RESTRAINTS 60
5.2.2.1 Limited applications of epigenomic data in toxicology 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Use of epigenetics in non-oncology applications 61
5.2.4 CHALLENGES 61
5.2.4.1 Challenges associated with epigenetic editing 61
5.2.4.1.1 Off-target effect 61
5.2.4.1.2 Other challenges 62
5.3 SCENARIOS ARISING OUT OF UNCERTAINTIES AFFECTING MARKET GROWTH 62
FIGURE 23 IMPACT OF UNCERTAINTIES ON MARKET GROWTH 62
5.4 IMPACT OF COVID-19 ON THE EPIGENETICS MARKET 63
TABLE 3 EPIGENETIC IMPLICATIONS IN CORONAVIRUS INFECTION AND THERAPY 63
5.5 PORTER’S FIVE FORCES ANALYSIS 64
TABLE 4 EPIGENETICS MARKET: PORTER’S FIVE FORCES ANALYSIS 64
5.5.1 THREAT OF NEW ENTRANTS 64
5.5.2 THREAT OF SUBSTITUTES 65
5.5.3 BARGAINING POWER OF BUYERS 65
5.5.4 BARGAINING POWER OF SUPPLIERS 65
5.5.5 DEGREE OF COMPETITION 65
5.6 ECOSYSTEM ANALYSIS 65
FIGURE 24 ECOSYSTEM ANALYSIS: EPIGENETICS MARKET 66
5.7 VALUE CHAIN ANALYSIS 66
FIGURE 25 VALUE CHAIN ANALYSIS: EPIGENETICS MARKET 67
5.8 SUPPLY CHAIN ANALYSIS 67
TABLE 5 SUPPLY CHAIN ECOSYSTEM 68
5.9 REGULATORY ANALYSIS 69
TABLE 6 KEY REGULATORY AGENCIES 70
6 EPIGENETICS MARKET, BY PRODUCT & SERVICE 72
6.1 INTRODUCTION 73
TABLE 7 EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 73
6.2 KITS & REAGENTS 73
TABLE 8 EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 74
TABLE 9 EPIGENETIC KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 74
TABLE 10 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 11 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 75
TABLE 12 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 75
6.2.1 ANTIBODIES 75
6.2.1.1 Increasing demand for recombinant antibodies for the detection of epigenetic targets propels the segment growth 75
TABLE 13 ANTIBODIES MARKET, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 14 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 76
TABLE 15 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 16 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 77
6.2.2 CHIP-SEQUENCING KITS & REAGENTS 77
6.2.2.1 Versatile applications of ChIP in epigenetic regulatory systems contribute to the segment’s dominant share 77
TABLE 17 CHIP-SEQ KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 77
TABLE 18 NORTH AMERICA: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 19 EUROPE: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 78
TABLE 20 ASIA PACIFIC: CHIP-SEQ KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 78
6.2.3 BISULFITE CONVERSION KITS & REAGENTS 79
6.2.3.1 Effectiveness of bisulfite conversion in gene-specific and genome-wide analyses to drive the demand for kits & reagents 79
TABLE 21 BISULFITE CONVERSION KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 79
TABLE 22 NORTH AMERICA: BISULFITE CONVERSION KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 23 EUROPE: BISULFITE CONVERSION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 24 ASIA PACIFIC: BISULFITE CONVERSION KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 80
6.2.4 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS 80
6.2.4.1 Whole-genome amplification maintains the relative proportions of genes present in the original pool, increasing its preference among researchers 80
TABLE 25 WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 26 NORTH AMERICA: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 27 EUROPE: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 28 ASIA PACIFIC: WHOLE-GENOME AMPLIFICATION KITS & REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.2.5 5-HMC & 5-MC ANALYSIS KITS & REAGENTS 82
6.2.5.1 Introduction of unique kits drives market growth 82
TABLE 29 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 82
TABLE 30 NORTH AMERICA: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 31 EUROPE: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 32 ASIA PACIFIC: 5-HMC & 5-MC ANALYSIS KITS & REAGENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.2.6 HISTONES 84
6.2.6.1 Importance of chromatin-associated proteins & histones in epigenetic research to drive the segment growth 84
TABLE 33 HISTONES MARKET, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 34 NORTH AMERICA: HISTONES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 84
TABLE 35 EUROPE: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 36 ASIA PACIFIC: HISTONES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
6.2.7 OTHER KITS & REAGENTS 85
TABLE 37 OTHER KITS & REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 38 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 86
TABLE 39 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 86
TABLE 40 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 86
6.3 ENZYMES 87
TABLE 41 EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 42 EPIGENETIC ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 43 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 88
TABLE 44 EUROPE: EPIGENETIC ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 88
TABLE 45 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 88
6.3.1 DNA-MODIFYING ENZYMES 89
6.3.1.1 Growing applications of DNA methylation to contribute to the segment’s dominant share 89
TABLE 46 DNA-MODIFYING ENZYMES MARKET, BY REGION,
2020–2027 (USD MILLION) 89
TABLE 47 NORTH AMERICA: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 89
TABLE 48 EUROPE: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 49 ASIA PACIFIC: DNA-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
6.3.2 PROTEIN-MODIFYING ENZYMES 90
6.3.2.1 Increasing pipeline of epigenetics-based drugs targeting histone-modifying enzymes to drive the segment growth 90
TABLE 50 PROTEIN-MODIFYING ENZYMES MARKET, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 51 NORTH AMERICA: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 52 EUROPE: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 91
TABLE 53 ASIA PACIFIC: PROTEIN-MODIFYING ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
6.3.3 OTHER ENZYMES 92
TABLE 54 OTHER ENZYMES MARKET, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 55 NORTH AMERICA: OTHER ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 93
TABLE 56 EUROPE: OTHER ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 93
TABLE 57 ASIA PACIFIC: OTHER ENZYMES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 93
6.4 INSTRUMENTS & ACCESSORIES 94
6.4.1 WIDE USAGE OF NGS INSTRUMENTS AND SONICATORS TO CONTRIBUTE TO THE SEGMENT REVENUE 94
TABLE 58 EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET, BY REGION,
2020–2027 (USD MILLION) 94
TABLE 59 NORTH AMERICA: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 60 EUROPE: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 61 ASIA PACIFIC: EPIGENETIC INSTRUMENTS & ACCESSORIES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 95
6.5 SOFTWARE 95
6.5.1 DEVELOPMENT OF VIABLE SOFTWARE SOLUTIONS FOR DNA METHYLATION, CHROMATIN, AND RNA ANALYSIS TO PROPEL SEGMENT GROWTH 95
TABLE 62 EPIGENETIC SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 63 NORTH AMERICA: EPIGENETIC SOFTWARE MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 96
TABLE 64 EUROPE: EPIGENETIC SOFTWARE MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 96
TABLE 65 ASIA PACIFIC: EPIGENETIC SOFTWARE MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 97
6.6 SERVICES 97
6.6.1 EXPANDING POOL OF PROVIDERS TO DRIVE THE SERVICES SEGMENT 97
TABLE 66 EPIGENETIC SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 67 NORTH AMERICA: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 98
TABLE 68 EUROPE: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 98
TABLE 69 ASIA PACIFIC: EPIGENETIC SERVICES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 99
7 EPIGENETICS MARKET, BY METHOD 100
7.1 INTRODUCTION 101
TABLE 70 EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 101
7.2 DNA METHYLATION 101
7.2.1 DNA METHYLATION TO DOMINATE THE METHODS MARKET TILL 2027 101
TABLE 71 EPIGENETICS MARKET FOR DNA METHYLATION, BY REGION,
2020–2027 (USD MILLION) 102
TABLE 72 NORTH AMERICA: EPIGENETICS MARKET FOR DNA METHYLATION,
BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 73 EUROPE: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 74 ASIA PACIFIC: EPIGENETICS MARKET FOR DNA METHYLATION, BY COUNTRY, 2020–2027 (USD MILLION) 103
7.3 HISTONE MODIFICATIONS 103
7.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE SEGMENT GROWTH 103
TABLE 75 COMMON HISTONE MODIFICATIONS AND RESPECTIVE LOCATIONS 103
TABLE 76 EPIGENETICS MARKET FOR HISTONE MODIFICATIONS, BY REGION,
2020–2027 (USD MILLION) 104
TABLE 77 NORTH AMERICA: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 78 EUROPE: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 79 ASIA PACIFIC: EPIGENETICS MARKET FOR HISTONE MODIFICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 105
7.4 OTHER METHODS 105
TABLE 80 EPIGENETICS MARKET FOR OTHER METHODS, BY REGION,
2020–2027 (USD MILLION) 106
TABLE 81 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER METHODS,
BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 82 EUROPE: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY,
2020–2027 (USD MILLION) 106
TABLE 83 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER METHODS, BY COUNTRY, 2020–2027 (USD MILLION) 107
8 EPIGENETICS MARKET, BY TECHNIQUE 108
8.1 INTRODUCTION 109
TABLE 84 EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 109

8.2 NGS 109
8.2.1 NGS OFFERS COMPREHENSIVE EPIGENETIC PROFILES,
WHICH DRIVES ADOPTION 109
TABLE 85 EPIGENETICS MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 86 NORTH AMERICA: EPIGENETICS MARKET FOR NGS, BY COUNTRY,
2020–2027 (USD MILLION) 110
TABLE 87 EUROPE: EPIGENETICS MARKET FOR NGS, BY COUNTRY,
2020–2027 (USD MILLION) 110
TABLE 88 ASIA PACIFIC: EPIGENETICS MARKET FOR NGS, BY COUNTRY,
2020–2027 (USD MILLION) 111
8.3 PCR & QPCR 111
8.3.1 RISING NUMBER OF PCR-BASED EPIGENETICS SERVICE PROVIDERS TO PROPEL THE SEGMENT GROWTH 111
TABLE 89 EPIGENETICS MARKET FOR PCR & QPCR, BY REGION,
2020–2027 (USD MILLION) 112
TABLE 90 NORTH AMERICA: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 91 EUROPE: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2020–2027 (USD MILLION) 112
TABLE 92 ASIA PACIFIC: EPIGENETICS MARKET FOR PCR & QPCR, BY COUNTRY,
2020–2027 (USD MILLION) 113
8.4 MASS SPECTROMETRY 113
8.4.1 GROWING DEMAND FOR MASS SPECTROMETRY IN HISTONE EPIGENETICS STUDIES TO DRIVE THE SEGMENT GROWTH 113
TABLE 93 EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY REGION,
2020–2027 (USD MILLION) 113
TABLE 94 NORTH AMERICA: EPIGENETICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 95 EUROPE: EPIGENETICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 96 ASIA PACIFIC: EPIGENETICS MARKET FOR MASS SPECTROMETRY,
BY COUNTRY, 2020–2027 (USD MILLION) 114
8.5 SONICATION 115
8.5.1 ADVENT OF IMPROVED HIGH-THROUGHPUT SONICATION TO PROPEL ITS ADOPTION IN EPIGENETICS STUDIES 115
TABLE 97 EPIGENETICS MARKET FOR SONICATION, BY REGION,
2020–2027 (USD MILLION) 115
TABLE 98 NORTH AMERICA: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 99 EUROPE: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2020–2027 (USD MILLION) 116
TABLE 100 ASIA PACIFIC: EPIGENETICS MARKET FOR SONICATION, BY COUNTRY,
2020–2027 (USD MILLION) 116
8.6 OTHER TECHNIQUES 116
TABLE 101 EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION,
2020–2027 (USD MILLION) 117
TABLE 102 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER TECHNIQUES,
BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 103 EUROPE: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 104 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2020–2027 (USD MILLION) 118
9 EPIGENETICS MARKET, BY APPLICATION 119
9.1 INTRODUCTION 120
TABLE 105 EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 120
9.2 ONCOLOGY 120
9.2.1 ONCOLOGY TO HOLD LARGEST SHARE OF THE APPLICATIONS
SEGMENT TILL 2027 120
TABLE 106 EPIGENOME-TARGETING CANCER DRUGS APPROVED OR IN CLINICAL TRIALS 121
TABLE 107 EPIGENETICS MARKET FOR ONCOLOGY, BY REGION,
2020–2027 (USD MILLION) 123
TABLE 108 NORTH AMERICA: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 109 EUROPE: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 123
TABLE 110 ASIA PACIFIC: EPIGENETICS MARKET FOR ONCOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 124
9.3 METABOLIC DISEASES 124
9.3.1 EMERGING ROLE OF DNA METHYLATION IN DIABETES MANAGEMENT
TO DRIVE THE SEGMENT GROWTH 124
TABLE 111 EPIGENETICS MARKET FOR METABOLIC DISEASES, BY REGION,
2020–2027 (USD MILLION) 125
TABLE 112 NORTH AMERICA: EPIGENETICS MARKET FOR METABOLIC DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 113 EUROPE: EPIGENETICS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 114 ASIA PACIFIC: EPIGENETICS MARKET FOR METABOLIC DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 126
9.4 IMMUNOLOGY 126
9.4.1 RISING DEMAND FOR EPIGENETICS PRODUCTS IN TUMOR AND TRANSPLANTATION IMMUNOLOGY TO DRIVE SEGMENT’S GROWTH 126
TABLE 115 EPIGENETICS MARKET FOR IMMUNOLOGY, BY REGION,
2020–2027 (USD MILLION) 126
TABLE 116 NORTH AMERICA: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 117 EUROPE: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY,
2020–2027 (USD MILLION) 127
TABLE 118 ASIA PACIFIC: EPIGENETICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 127
9.5 DEVELOPMENTAL BIOLOGY 128
9.5.1 GROWING R&D IN DEVELOPMENTAL BIOLOGY TO PROPEL THE SEGMENT’S GROWTH 128
TABLE 119 EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY, BY REGION,
2020–2027 (USD MILLION) 128
TABLE 120 NORTH AMERICA: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION) 128
TABLE 121 EUROPE: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 122 ASIA PACIFIC: EPIGENETICS MARKET FOR DEVELOPMENTAL BIOLOGY,
BY COUNTRY, 2020–2027 (USD MILLION) 129
9.6 CARDIOVASCULAR DISEASES 129
9.6.1 EMERGING ROLE OF EPIGENETICS IN UNDERSTANDING THE ETIOLOGY OF CARDIOVASCULAR DISEASES TO PROPEL PRODUCT ADOPTION 129
TABLE 123 EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 130
TABLE 124 NORTH AMERICA: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 125 EUROPE: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 126 ASIA PACIFIC: EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES,
BY COUNTRY, 2020–2027 (USD MILLION) 131
9.7 OTHER APPLICATIONS 131
TABLE 127 EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION,
2020–2027 (USD MILLION) 131
TABLE 128 NORTH AMERICA: EPIGENETICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 129 EUROPE: EPIGENETICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 130 ASIA PACIFIC: EPIGENETICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 132

10 EPIGENETICS MARKET, BY END USER 133
10.1 INTRODUCTION 134
TABLE 131 EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 134
10.2 ACADEMIC & RESEARCH INSTITUTES 134
10.2.1 HIGH SHARE ATTRIBUTED TO RISING COLLABORATIONS AMONG RESEARCH INSTITUTES AND DEMAND FOR CANCER EPIGENETICS 134
TABLE 132 EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 135
TABLE 133 NORTH AMERICA: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 134 EUROPE: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 135 ASIA PACIFIC: EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 136
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 136
10.3.1 HIGH NUMBER OF CLINICAL TRIALS FOR EPIGENETICS-BASED DRUGS TO DRIVE THE SEGMENT GROWTH 136
TABLE 136 EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 137
TABLE 137 NORTH AMERICA: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 138 EUROPE: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 139 ASIA PACIFIC: EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 138
10.4 HOSPITALS & CLINICS 138
10.4.1 RISING IMPORTANCE OF DNA METHYLATION MEASUREMENTS TO DRIVE SEGMENT GROWTH 138
TABLE 140 EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY REGION,
2020–2027 (USD MILLION) 139
TABLE 141 NORTH AMERICA: EPIGENETICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 142 EUROPE: EPIGENETICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020–2027 (USD MILLION) 139
TABLE 143 ASIA PACIFIC: EPIGENETICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2020–2027 (USD MILLION) 140
11 EPIGENETICS MARKET, BY REGION 141
11.1 INTRODUCTION 142
TABLE 144 EPIGENETICS MARKET, BY REGION, 2020–2027 (USD MILLION) 142
11.2 NORTH AMERICA 142
FIGURE 26 NORTH AMERICA: EPIGENETICS MARKET SNAPSHOT 143
TABLE 145 NORTH AMERICA: EPIGENETICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 143
TABLE 146 NORTH AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 144
TABLE 147 NORTH AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 148 NORTH AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 145
TABLE 149 NORTH AMERICA: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION) 145
TABLE 150 NORTH AMERICA: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 145
TABLE 151 NORTH AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 146
TABLE 152 NORTH AMERICA: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 146
11.2.1 US 146
11.2.1.1 A strong network of well-established epigenetic product manufacturers is the key growth contributor 146
TABLE 153 US: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 147
TABLE 154 US: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 147
TABLE 155 US: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
TABLE 156 US: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 148
TABLE 157 US: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 148
TABLE 158 US: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 149
TABLE 159 US: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 149
11.2.2 CANADA 149
11.2.2.1 Government initiatives to boost epigenetics research contribute to the market growth 149
TABLE 160 CANADA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 150
TABLE 161 CANADA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 150
TABLE 162 CANADA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 151
TABLE 163 CANADA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 151
TABLE 164 CANADA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 151
TABLE 165 CANADA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 152
TABLE 166 CANADA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 152
11.3 EUROPE 152
TABLE 167 EUROPE: EPIGENETICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 168 EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 153
TABLE 169 EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 170 EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 154
TABLE 171 EUROPE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 154
TABLE 172 EUROPE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 154
TABLE 173 EUROPE: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 155
TABLE 174 EUROPE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 155
11.3.1 GERMANY 155
11.3.1.1 Significant investments in the NGS market space in Germany expected to boost the uptake of epigenetics products 155
TABLE 175 GERMANY: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 156
TABLE 176 GERMANY: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 156
TABLE 177 GERMANY: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 156
TABLE 178 GERMANY: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 157
TABLE 179 GERMANY: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 157
TABLE 180 GERMANY: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 157
TABLE 181 GERMANY: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 158
11.3.2 UK 158
11.3.2.1 Rising acceptance of genome-based diagnostic techniques to drive the UK epigenetics market 158
TABLE 182 UK: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 158
TABLE 183 UK: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 159
TABLE 184 UK: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 185 UK: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 159
TABLE 186 UK: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 160
TABLE 187 UK: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160
TABLE 188 UK: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 160
11.3.3 FRANCE 161
11.3.3.1 Growing demand for PCR technologies propelled by favorable government initiatives to boost the market growth 161
TABLE 189 FRANCE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 161
TABLE 190 FRANCE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 191 FRANCE: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 162
TABLE 192 FRANCE: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 162
TABLE 193 FRANCE: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 162
TABLE 194 FRANCE: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 163
TABLE 195 FRANCE: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 163
11.3.4 REST OF EUROPE 163
TABLE 196 REST OF EUROPE: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 164
TABLE 197 REST OF EUROPE: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 198 REST OF EUROPE: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 165
TABLE 199 REST OF EUROPE: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION) 165
TABLE 200 REST OF EUROPE: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 165
TABLE 201 REST OF EUROPE: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 166
TABLE 202 REST OF EUROPE: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 166
11.4 ASIA PACIFIC 167
FIGURE 27 ASIA PACIFIC: EPIGENETICS MARKET SNAPSHOT 167
TABLE 203 ASIA PACIFIC: EPIGENETICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 168
TABLE 204 ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 168
TABLE 205 ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 169
TABLE 206 ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 169
TABLE 207 ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION) 169
TABLE 208 ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 170
TABLE 209 ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 170
TABLE 210 ASIA PACIFIC: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 170
11.4.1 JAPAN 171
11.4.1.1 Research-academia collaborations have driven awareness of epigenetics in the country 171
TABLE 211 JAPAN: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 171
TABLE 212 JAPAN: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 172
TABLE 213 JAPAN: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 214 JAPAN: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 172
TABLE 215 JAPAN: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 216 JAPAN: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 173
TABLE 217 JAPAN: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 173
11.4.2 CHINA 174
11.4.2.1 Increasing research on genomics and high demand for personalized medicine to propel the Chinese market 174
TABLE 218 CHINA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 174
TABLE 219 CHINA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 175
TABLE 220 CHINA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 221 CHINA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 175
TABLE 222 CHINA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 223 CHINA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176
TABLE 224 CHINA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 176
11.4.3 INDIA 177
11.4.3.1 Activities to strengthen genomics research by expanding the base of biotechnology facilities to drive market growth 177
TABLE 225 INDIA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 177
TABLE 226 INDIA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 178
TABLE 227 INDIA: EPIGENETIC ENZYMES MARKET, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 228 INDIA: EPIGENETICS MARKET, BY METHOD, 2020–2027 (USD MILLION) 178
TABLE 229 INDIA: EPIGENETICS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 179
TABLE 230 INDIA: EPIGENETICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 179
TABLE 231 INDIA: EPIGENETICS MARKET, BY END USER, 2020–2027 (USD MILLION) 179
11.4.4 REST OF ASIA PACIFIC 180
TABLE 232 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 180
TABLE 233 REST OF ASIA PACIFIC: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 234 REST OF ASIA PACIFIC: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 181
TABLE 235 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION) 181
TABLE 236 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 181
TABLE 237 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 182
TABLE 238 REST OF ASIA PACIFIC: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 182
11.5 LATIN AMERICA 182
11.5.1 ADVANCEMENTS IN EPIGENETIC ANALYSIS AND CHARACTERIZATION TO BOOST THE UPTAKE OF MARKET PRODUCTS 182
TABLE 239 LATIN AMERICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE,
2020–2027 (USD MILLION) 183
TABLE 240 LATIN AMERICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 183
TABLE 241 LATIN AMERICA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 184
TABLE 242 LATIN AMERICA: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION) 184
TABLE 243 LATIN AMERICA: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 184
TABLE 244 LATIN AMERICA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 185
TABLE 245 LATIN AMERICA: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 185
11.6 MIDDLE EAST & AFRICA 185
11.6.1 RISING FUNDING AND PARTNERSHIPS IN RESEARCH TO BOOST MARKET GROWTH IN THE MIDDLE EAST & AFRICA 185
TABLE 246 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 186
TABLE 247 MIDDLE EAST & AFRICA: EPIGENETIC KITS & REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 248 MIDDLE EAST & AFRICA: EPIGENETIC ENZYMES MARKET, BY TYPE,
2020–2027 (USD MILLION) 187
TABLE 249 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY METHOD,
2020–2027 (USD MILLION) 187
TABLE 250 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 187
TABLE 251 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 188
TABLE 252 MIDDLE EAST & AFRICA: EPIGENETICS MARKET, BY END USER,
2020–2027 (USD MILLION) 188
12 COMPETITIVE LANDSCAPE 189
12.1 INTRODUCTION 189
12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 189
FIGURE 28 EPIGENETICS MARKET: STRATEGIES ADOPTED 189
12.3 MARKET SHARE ANALYSIS 190
FIGURE 29 EPIGENETICS MARKET: MARKET SHARE ANALYSIS OF TOP 5 PLAYERS (2021) 190
12.4 REVENUE SHARE ANALYSIS (TOP 5 MARKET PLAYERS) 191
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST 2-3 YEARS 192
12.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS) 192
FIGURE 31 EPIGENETICS MARKET: COMPANY EVALUATION MATRIX, 2021 193
12.5.1 STARS 193
12.5.2 EMERGING LEADERS 193
12.5.3 PERVASIVE PLAYERS 193
12.5.4 PARTICIPANTS 194
12.5.5 COMPETITIVE BENCHMARKING—STARTUPS/SMES 194
TABLE 253 EPIGENETICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 194
TABLE 254 EPIGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES] 195

12.6 COMPETITIVE SCENARIO AND TRENDS 196
12.6.1 PRODUCT LAUNCHES 196
TABLE 255 EPIGENETICS MARKET: PRODUCT LAUNCHES 196
12.6.2 DEALS 196
TABLE 256 EPIGENETICS MARKET: ACQUISITIONS 196

13 COMPANY PROFILES 197
13.1 KEY COMPANIES 197
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 THERMO FISHER SCIENTIFIC INC. 197
TABLE 257 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 197
FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 198
13.1.2 ILLUMINA, INC. 200
TABLE 258 ILLUMINA, INC.: BUSINESS OVERVIEW 200
FIGURE 33 ILLUMINA, INC.: COMPANY SNAPSHOT 201
13.1.3 PACIFIC BIOSCIENCES 204
TABLE 259 PACBIO: BUSINESS OVERVIEW 204
FIGURE 34 PACBIO: COMPANY SNAPSHOT 204
13.1.4 ABCAM PLC. 207
TABLE 260 ABCAM PLC.: BUSINESS OVERVIEW 207
FIGURE 35 ABCAM PLC: COMPANY SNAPSHOT 208
13.1.5 MERCK KGAA 211
TABLE 261 MERCK KGAA: BUSINESS OVERVIEW 211
FIGURE 36 MERCK KGAA: COMPANY SNAPSHOT 212
13.1.6 BIO-RAD LABORATORIES, INC. 214
TABLE 262 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 214
FIGURE 37 BIO-RAD LABORATORIES: COMPANY SNAPSHOT 215
13.1.7 ACTIVE MOTIF 217
TABLE 263 ACTIVE MOTIF: BUSINESS OVERVIEW 217
13.1.8 NEW ENGLAND BIOLABS 221
TABLE 264 NEW ENGLAND BIOLABS: BUSINESS OVERVIEW 221
13.1.9 QIAGEN 224
TABLE 265 QIAGEN: BUSINESS OVERVIEW 224
FIGURE 38 QIAGEN: COMPANY SNAPSHOT 225
13.1.10 ZYMO RESEARCH CORPORATION 227
TABLE 266 ZYMO RESEARCH CORPORATION: BUSINESS OVERVIEW 227
13.1.11 PERKINELMER INC. 230
TABLE 267 PERKINELMER INC.: BUSINESS OVERVIEW 230
13.1.12 DIAGENODE 232
TABLE 268 DIAGENODE: BUSINESS OVERVIEW 232
13.1.13 F. HOFFMANN-LA ROCHE LTD 234
TABLE 269 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 234
FIGURE 39 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT 234
13.1.14 PROMEGA CORPORATION 236
TABLE 270 PROMEGA CORPORATION: BUSINESS OVERVIEW 236
13.2 OTHER PLAYERS 237
13.2.1 EPIGENTEK GROUP INC. 237
13.2.2 EPICYPHER 237
13.2.3 EVERON LIFE SCIENCES 238
13.2.4 FIOS GENOMICS 238
13.2.5 GENOMESCAN 238
13.2.6 CREATIVE BIOGENE 239
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 240
14.1 DISCUSSION GUIDE 240
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 245
14.3 AVAILABLE CUSTOMIZATIONS 247
14.4 RELATED REPORTS 247
14.5 AUTHOR DETAILS 248

★調査レポート[エピジェネティクスのグローバル市場予測(~2027):キット&試薬、酵素、機器&付属品、ソフトウェア、サービス] ( Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027 / BT2775-22) 販売に関する免責事項
[エピジェネティクスのグローバル市場予測(~2027):キット&試薬、酵素、機器&付属品、ソフトウェア、サービス] ( Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Software, Service), Method (DNA Methylation), Technique (NGS, PCR & qPCR), Application (Oncology, Immunology), End User - Global Forecast to 2027 / BT2775-22) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆